Current Research Studies

SC-N181: Evaluating financial toxicity in pediatric oncology through the multi-site validation of a novel caregiver-reported outcome measure

SC-N181: PRICE Measure Validation

  • Condition(s): Anus, Bones and Joints, Brain and Nervous System, Breast, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Ill-Defined Sites, Kaposi's Sarcoma, Kidney, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, Skin, Multiple Myeloma, Mycosis Fungoides, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Non-malignant Disease, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Hematopoietic, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Urinary Bladder
  • Phase: N/A
  • Clinicaltrials.gov ID: NCT33333333

What is the goal of the study?

The goal of this study is to validate a novel caregiver-reported outcome measure of financial toxicity in pediatric oncology settings, called the Parent-Reported Instrument of Costs and Experiences with financial toxicity (PRICE) measure. The PRICE measure was developed by our team through a deliberate process consisting of qualitative concept elicitation, expert panel review, and cognitive pretesting with caregivers. It has versions in English and Spanish. In validating the PRICE measure in both of these languages, we will also gather critical information to characterize the landscape of financial toxicity and address an important knowledge gap in our field. This will be a two-site cross-sectional survey study of parents/guardians of children with cancer treated at Seattle Children?s Hospital or Texas Children?s Hospital. We will invite parents to complete the PRICE measure, along with 4 other concurrent (related) measures and a short demographic survey. Together, the surveys will take 25-30 minutes to complete. The modality of survey administration would be based on patient preference: electronic (default), paper, by phone, or in person. We will also capture clinical and household information for correlation from the electronic health record. For analysis, structural equation modeling will be applied to evaluate the measure?s psychometric properties. We will use Pearson correlations and multivariable regression models to test convergent/divergent validity, as well as possible associations between PRICE scores and family/household factors. Finally, we will follow-up event-free and overall survival to assess whether financial toxicity is associated with outcomes.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: